Pfizer Inc, the largest U.S. drugmaker, said it plans to separate its commercial operations into two units, mainly for patent-protected brands, and a third for generics.
Earlier this year, Pfizer said it would begin examining the finances of its patent-protected unit, which it calls its "innovative" business, and its generic operation, called its "value" business, to decide whether to spin off the generics operation. It said the review would take three years. Read more